Podcast appearances and mentions of Peter Goodwin

  • 33PODCASTS
  • 275EPISODES
  • 15mAVG DURATION
  • ?INFREQUENT EPISODES
  • Jun 10, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about Peter Goodwin

Latest podcast episodes about Peter Goodwin

BlockHash: Exploring the Blockchain
Ep. 527 Peter Goodwin | Turning Ideas into Businesses with AI on the idea-L Platform

BlockHash: Exploring the Blockchain

Play Episode Listen Later Jun 10, 2025 39:24


For episode 527, Brandon Zemp is joined by Peter Goodwin CEO & founder of idea-L, an AI and Web3 platform equipping entrepreneurs with the resources to transform any business idea into a reality.Using AI-powered technology, the platform allows entrepreneurs to assess the viability of an idea early in the ideation process, enabling them to make data-driven decisions on if, and how to move forward before investing significant time, capital, and resources.⏳ Timestamps: 0:00 | Introduction1:04 | Who is Peter Goodwin?2:40 | UAE hub for AI3:47 | What is idea-L?8:18 | Why Entrepreneurs struggle12:15 | What is the process behind idea-L?17:12 | IRP, IFP & DeVC Fund20:52 | Criteria to apply24:48 | Capital funding caps27:17 | VC ecosystem today33:26 | idea-L roadmap 

Pediatric Physical Therapy - Pediatric Physical Therapy Podcast

Burning Topic for Pediatric Physical Therapists: In the USA and Globally Pediatric Physical Therapy Editor-in-Chief Linda Fetters PhD, PT, FAPTA, gives reporter Peter Goodwin her assessment of the organizational crisis that has enveloped pediatric and other clinicians in the USA and globally since the new Administration took office in 2025.Predictors of Length of Physical Therapy Care for Infants With Congenital Torticollis. We talk with Pediatric Physical Therapy author Heather R Aker PT DHSc, Physical Therapist, at the Children's Hospital, Philadelphia, about her research findings published in Pediatric Physical Therapy on: Predictors of Length of Physical Therapy Care for Infants with Congenital Torticollis. Pediatric Physical Therapy Editor-in-Chief Linda Fetters adds her comments.PLEASE JOIN THE CONVERSATION!! We need to know your views, and we would love you to take part in the podcast. Please send us your perspectives and interpretations of the issues you would like us to air on the podcast. You can contact us at: E-mail: pediatricphysicaltherapy@audiomedica.comText Messages, WhatsApp, What's App Video or Audio: +44 7771 642 333

Oncology Times - OT Broadcasts from the iPad Archives
Tumor-Agnostic Classifier & Screener Aids Targeted Drug Development

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Jan 10, 2025 9:21


A tumor-agnostic classifier and screening tool was announced at ESMO Congress 2024 in Barcelona. It was created to make it easier and quicker to develop new drugs that have specific molecular targets, and thus have potential anti-cancer efficacy irrespective of tumor type or location. The ESMO Tumour-Agnostic Classifier and Screener was the result of work by a multidisciplinary team of international experts led by the ESMO Precision Medicine Working Group. At the conference, Benedikt Westphalen, MD, a medical oncologist and molecular biologist who is Head of the Precision Oncology Program at the University of Munich in Germany, talked about the details with Oncology Times correspondent Peter Goodwin.

Oncology Times - OT Broadcasts from the iPad Archives
Antibody-Drug Conjugate “Promising Efficacy” in HER2-Positive and HER2-Low Breast Cancer

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Nov 15, 2024 9:24


In a Phase I study with 318 patients in China and Australia the antibody-drug conjugate (ADC) IBI354 was found to be safe and have promising efficacy in patients whose breast and other solid tumors tested positive for HER2 or were categorized as “HER2-low.” At ESMO Congress 2024, the study also reported a low rate of interstitial lung disease in patients treated with the ADC. Oncology Times correspondent Peter Goodwin talked with Christina Teng, PhD, the presenting author of the new research from Scientia Clinical Research and the Prince of Wales Hospital in Sydney, Australia.

Oncology Times - OT Broadcasts from the iPad Archives
Recurrent Glioma: Encouraging Responses to Autologous Myeloid Dendritic Cell Therapy

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Oct 30, 2024 10:45


When patients with recurrent high-grade glioblastoma were treated with autologous myeloid dendritic cells, they had clinical responses described as “encouraging” in a Phase I clinical trial reported at the ESMO Congress 2024. Cells harvested from each patient were injected directly into the resection cavity brain tissue lining after surgery. Patients also received intracranial injections of the checkpoint inhibitor combination: nivolumab + ipilimumab. At the conference, Oncology Times reporter Peter Goodwin caught up with lead author of the study, Bart Neyns, MD, PhD, Head of Medical Oncology at the Vrije Universiteit Brussel in the University Hospital Brussels Faculty of Medicine & Pharmacy in Belgium.

Oncology Times - OT Broadcasts from the iPad Archives
Preoperative Chemoradiation Ruled Out for Gastric or GE Junction Resectable Adenocarcinoma

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Oct 30, 2024 8:07


The addition of preoperative chemoradiation therapy to perioperative chemotherapy did not improve overall survival as compared with perioperative chemotherapy alone in patients with resectable gastric or gastroesophageal junction adenocarcinomas. The multi-continent, Phase III randomized TOPGEAR trial has definitively found no benefit from adding radiation before surgery in terms of overall or progression-free survival. This clear finding was reported simultaneously in the New England Journal of Medicine and at the ESMO 2024 Congress held in Barcelona, Spain. After presenting the findings , first author Trevor Leong, MD, Radiation Oncologist at the Peter McCallum Cancer Centre in Melbourne, Australia, met up with Oncology Times reporter Peter Goodwin.

Oncology Times - OT Broadcasts from the iPad Archives
Perioperative Checkpoint Inhibition Better for Muscle-Invasive Bladder Cancer

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Oct 30, 2024 9:00


Patients with muscle-invasive bladder cancer experienced “clinically meaningful” improvements in key outcomes—event-free survival and overall survival—when the immune checkpoint inhibitor durvalumab was added to their standard neoadjuvant chemotherapy. This was in research findings, reported at the ESMO Congress 2024, from the NIAGARA randomized Phase Ill trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in patients with cisplatin-eligible muscle-invasive bladder cancer. After his talk at the ESMO Barcelona conference, first author Thomas Powles, MBBS, MRCP, MD, from the Barts Cancer Institute at Queen Mary University of London, UK, met up with Oncology Times correspondent Peter Goodwin.

Oncology Times - OT Broadcasts from the iPad Archives
Advanced Melanoma: CheckMate 067 10-Year Data Show Prognoses Transformed By Checkpoint Inhibitors

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Oct 30, 2024 14:28


Sustained responses and long-term overall survival have resulted from checkpoint inhibitor therapy for advanced melanoma, transforming the prognosis for as many as half of patients. This is according to 10-year survival outcomes from the Phase Ill CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma that were reported at the ESMO Congress 2024. At the conference, Oncology Times reporter, Peter Goodwin, caught up with James Larkin, FRCP, PhD, Professor and Medical Oncologist at the Royal Marsden Hospital in London.

Oncology Times - OT Broadcasts from the iPad Archives
Resectable Stage III Melanoma: Unprecedented Survival Benefit With Pure Checkpoint Inhibitor Neoadjuvant Therapy

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Oct 23, 2024 6:17


A large, expanded-cohort pooled analysis of neoadjuvant immunotherapy for patients with resectable Stage III melanoma has reported very high rates of durable survival. The findings from the world’s biggest center of expertise in melanoma were announced at ESMO Congress 2024. The study included patients from clinical trials and real-world studies who had pure immune checkpoint inhibitor neoadjuvant therapy, or combinations including BRAF/MEK targeted therapy. After giving her talk in Barcelona, lead investigator Georgina Long, AO, PhD, MBBS, FRACP, Professor and Co-Medical Director at the Melanoma Institute Australia, University of Sydney, gave Oncology Times reporter Peter Goodwin the details.

Oncology Times - OT Broadcasts from the iPad Archives
Therapeutic mRNA Vaccine Brings New Hope in Glioblastoma

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Oct 23, 2024 12:05


Patients with newly diagnosed, surgically resected MGMT-unmethylated glioblastoma may benefit from treatment with a therapeutic mRNA vaccine called CVGBM, according to findings from a first-in-human, Phase I safety and dose-escalation study from Tübingen, Germany, reported at the ESMO Congress 2024 held in Barcelona. The CVGBM vaccine encodes multiple molecular features derived from tumor-associated antigens, all of which were judged to be potentially relevant in glioblastoma. After reporting her group’s findings to the ESMO Barcelona meeting, first author Ghazaleh Tabatabai, MD, PhD, a neurologist, Professor of Neuro-Oncology, and Chair of the Department of Neurology and Interdisciplinary Neuro-Oncology at the University Hospital, Tübingen, Germany, talked about the findings with Oncology Times reporter Peter Goodwin.

Oncology Times - OT Broadcasts from the iPad Archives
Circulating Tumor DNA Directs Precision Management for Ovarian Cancer

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Oct 15, 2024 10:01


Drug resistance can be delayed and treatment outcomes predicted in patients with ovarian cancer with the help of relatively low-cost molecular precision management techniques using liquid biopsies. These are being developed by a team at the University of California in Los Angeles (UCLA) led by Jian Yu Rao, MD, Vice Chair of Diagnostic Technology Innovation at UCLA, where he is also Chief of Cytopathology and Director of International Telepathology. At the 2024 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) held in Xiamen, China, Rao gave Oncology Times reporter Peter Goodwin details of the molecular methods he had just outlined to the conference.

Oncology Times - OT Broadcasts from the iPad Archives
Cardio-Oncology: Many Cancer Treatment Cardiotoxicities Still to Be Understood

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Oct 14, 2024 13:04


The escalating danger of cardiac toxicity posed by a range of increasingly effective anti-cancer therapies is insufficiently understood, according to the head of a world center of excellence for the study of cardio-oncology in northern China. At a special session devoted to cardio-oncology held at the Chinese Society of Clinical Oncology (CSCO) 2024 Annual Meeting, the challenges of cardio-oncology were examined by a committee of experts with reference to the CSCO Clinical Practice Guide for Tumor Cardiology. Among the speakers was cardiologist Yun-Long Xia, MD, PhD, FESC, FHRS, Head of Cardiovascular Medicine at Dalian Medical University in China. Afterward, he talked about their conclusions with Oncology Times reporter Peter Goodwin.

Oncology Times - OT Broadcasts from the iPad Archives
Global Cooperation on Antibody-Drug Conjugates: Key Driver of Progress in HER2-Dependent Metastatic Breast Cancer Treatment

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Oct 7, 2024 8:43


An assessment of progress with antibody-drug conjugates (ADCs) for the treatment of HER2-dependent metastatic breast cancer was given at the 2024 Chinese Society of Clinical Oncology (CSCO) Annual Meeting. The President-Elect of the European Society for Medical Oncology (ESMO), Giuseppe Curigliano, MD, PhD, Director of the Early Drug Development for Innovative Therapies Division at the European Institute of Oncology and the University of Milano in Italy, told Oncology Times reporter Peter Goodwin about the broadening scope of ADCs in breast cancer and his reasons for encouraging ESMO and CSCO to continue to expand their co-operation.

Oncology Times - OT Broadcasts from the iPad Archives
Emerging Potential for Cell Therapies in Ovarian Cancer and Other Solid Tumors

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Oct 7, 2024 9:51


Details of the expanding range of cell therapies beyond hematologic malignancy were reported at the 2024 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) by Oliver Dorigo, MD, PhD, Director of the Division of Gynecologic Oncology at the Stanford Women's Cancer Center in Stanford University. After his talk at CSCO, Dorigo told Oncology Times reporter Peter Goodwin about the promise cell therapies held for improving outcomes in ovarian cancer and other solid tumors, as well as the benefit of the exchange of ideas flowing between China, U.S., and other global players in this young science.

Oncology Times - OT Broadcasts from the iPad Archives
World-Wide Clinical Perspectives from Chinese Society of Clinical Oncology's Globally Upscale 2024 Annual Meeting

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Oct 4, 2024 8:21


At the opening session of the Chinese Society of Clinical Oncology (CSCO) 2024 Annual Meeting, attended by nearly 30,000 cancer specialists, Oncology Times reporter Peter Goodwin asked the President of CSCO, Xu Ruihua, MD, PhD, Professor and President of Sun Yat-sen University Cancer Center in Guangzhou, China, to talk about some of the ways that progress in cancer treatments had been made more productive by co-operation between Chinese and Western centers of oncology excellence.

Oncology Times - OT Broadcasts from the iPad Archives
Breastfeeding is Safe After Treatment for BRCA-Positive Breast Cancer

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Oct 4, 2024 7:26


Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the 2024 Annual meeting of the European Society for Medical Oncology, ESMO. The Scientific Chair of the meeting, Rebecca Dent MD, Deputy Chief Executive Officer of the National Cancer Center in Singapore, told Oncology Times reporter Peter Goodwin about some of the key areas of progress covered by the meeting that she was most excited about.

Oncology Times - OT Broadcasts from the iPad Archives
Breastfeeding is Safe After Treatment for BRCA-Positive Breast Cancer

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Sep 27, 2024 7:26


A large international cohort study has found that women testing positive for the BRCA mutation who chose to breastfeed their babies after treatment for their breast cancer faced no additional risk to their cancer outcomes. OncTimesTalk correspondent Peter Goodwin talked with Eva Blondeaux, MD, Medical Oncologist in the Epidemiology Unit at the IRCCS Ospedale Policlinico San Martino, Genoa, Italy, and the author of the study, after her presentation of the new data at the ESMO 2024 Congress.

Oncology Times - OT Broadcasts from the iPad Archives
Breastfeeding After Hormone Receptor-Positive Breast Cancer: No Detectable Risk for Patients

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Sep 26, 2024 11:33


Women who chose to interrupt their endocrine therapy after their breast cancer surgery to have a baby faced no additional cancer risk, according to data from the POSITIVE study reported at the ESMO Congress 2024. In Barcelona, OncTimesTalk reporter Peter Goodwin met up with Fedro Peccatori, MD, PhD, Director of the Fertility and Procreation Unit in the Division of Gynecologic Oncology at the European Institute of Oncology, Milan, Italy, after he reported his group’s findings. “Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial,” Peccatori noted.

Oncology Times - OT Broadcasts from the iPad Archives
HPV Vaccination Prevents HIV-Related Cancers in Men

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Jul 10, 2024 6:02


HPV vaccination for girls and boys in the United States has led to a real-world reduction of oral head and neck cancers in men, as well as the already documented prevention of cervical cancers in women, even though uptake of the vaccine in the U.S. has been suboptimal. This is according to findings from a retrospective analysis of HPV-associated cancer incidence, reported at the 2024 ASCO Annual Meeting. At the Chicago meeting, OncTimesTalk reporter Peter Goodwin met up with the lead author of the research, Jefferson DeKloe, BSc, from the Department of Otolaryngology at Thomas Jefferson University in Philadelphia.

Oncology Times - OT Broadcasts from the iPad Archives
Proton Pump Inhibitors Bigger Impact on Dasatinib Efficacy in CML Than Previously Thought

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Jul 9, 2024 4:31


Although co-medication with proton pump inhibitors (PPI) is not advised for patients being treated with dasatanib for their chronic myeloid leukemia (CML), confirmation that this recommendation is often overlooked has been reported in a study led by Torsten Dahlén, a PhD student at the Karolinska Institutet in Stockholm, Sweden. Furthermore, the study found a higher than previously reported negative interaction of PPI comedication on crystalline dasatinib bioavailability that may compromise clinical efficacy and risk CML disease progression. The latest findings from the study were reported in a poster session at the 2024 ASCO Annual Meeting where Oncology Times reporter Peter Goodwin met up with Olof Harlin, PhD, of Xspray Pharma, based in Solna, near Stockholm, Sweden.

Oncology Times - OT Broadcasts from the iPad Archives
Immune-Related Adverse Events Predict Response to Checkpoint Inhibitor Monotherapy in Advanced Head & Neck Cancers

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Jul 9, 2024 6:28


Patients who had immune-related adverse events had better responses and lived longer than those who didn't. This was a real-world observational study of patients with recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint inhibitor monotherapy, reported at the 2024 ASCO Annual Meeting. OncTimesTalk reporter Peter Goodwin caught up with the lead study author Chiara Gottardi, MD, who specializes in head and neck cancer in the Department of Surgery, Oncology, and Gastroenterology in the Istituto Oncologico Veneto at the University of Padova in Italy.

Oncology Times - OT Broadcasts from the iPad Archives
A Multi-Drug Algorithm Used to Accurately Predict Best First-Line Treatments in Patients With Newly Diagnosed Acute Myeloid Leukemia

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Jul 9, 2024 7:39


A mathematical model using data from routine diagnostic samples has been found to accurately predict individual patient responses to the main candidate first-line treatments for acute myeloid leukemia. Findings from a validation study in independent patient cohorts led by researchers from the Barts Cancer Institute at the Queen Mary University of London were reported at a poster session of the 2024 ASCO Annual Meeting. Oncology Times correspondent Peter Goodwin attended the session and talked with the second author of the study, Weronika E. Borek PhD, a Bioinformatics Technical Lead at Kinomica Limited in London.

Oncology Times - OT Broadcasts from the iPad Archives
Neoadjuvant Checkpoint Inhibitor Combination Beats Standard Surgery With Adjuvant Immunotherapy in Macroscopic, Resectable Stage III Melanoma

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Jun 25, 2024 11:34


A combination of two checkpoint inhibitors used as neoadjuvant therapy for macroscopic, resectable Stage III melanoma brought a highly statistically significant improvement over the standard of care: surgery followed by checkpoint inhibition (therapeutic lymph node dissection followed by adjuvant therapy with nivolumab, pembrolizumab or, in BRAFmut melanoma, dabrafenib + trametinib). This research was reported from the ASCO 2024 Annual Meeting and highlighted the NADINA trial from the Netherlands. After his session at ASCO, the lead author of NADINA, Christian U. Blank, MD, PhD, from the Netherlands Cancer Institute and Antoni van Leeuwenhook Hospital, Amsterdam, the Netherlands, met up with Oncology Times reporter Peter Goodwin to discuss the findings.

Oncology Times - OT Broadcasts from the iPad Archives
Telehealth Triumphs for Palliative Care Delivery in Patients With Lung Cancer

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Jun 25, 2024 14:15


Not only can palliative care be delivered effectively by telehealth to patients with advanced non-small cell lung cancer, it's also as effective as face-to-face delivery by specialist clinicians, according to a study reported at the 2024 ASCO Annual Meeting. In addition, telehealth turned out to be more popular. For the Oncology Times podcast, OncTimesTalk, correspondent Peter Goodwin spoke with Joseph A. Greer, PhD, lead author of the study and Co-Director of the Cancer Outcomes Research and Education Program at Massachusetts General Hospital and Harvard Medical School.

Oncology Times - OT Broadcasts from the iPad Archives
MUC-1 Vaccine Delays Breast Cancer Distant Recurrence & Extends Survival

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Jun 25, 2024 9:02


When the mucin-1 (MUC-1) vaccine tecemotide was added to standard-of-care neoadjuvant systemic therapy, investigators in Austria found improved long-term outcomes in women with early breast cancer. Individuals vaccinated with tecemotide had markedly longer distant recurrence-free and overall survival. This was in the randomized prospective ABCSG-34 trial presented at the 2024 ASCO Annual Meeting. Oncology Times reporter Peter Goodwin met up in Chicago with the lead study author, Christian F. Singer MD, a gynecologist specializing in breast cancer at the Department of Obstetrics and Gynecology and the Comprehensive Cancer Center of the Medical University of Vienna, in Vienna, Austria.

Oncology Times - OT Broadcasts from the iPad Archives
Lymphadenectomy Can Be Safely Omitted for Patients With Advanced Epithelial Ovarian Cancer Lacking Suspicious Lymph Nodes

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Jun 25, 2024 10:53


The CARACO prospective, multi-institutional, Phase III trial, among patients with newly diagnosed advanced epithelial ovarian cancer, found that lymphadenectomy should be omitted in patients with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery. This finding from the University of Nantes was reported at the 2024 ASCO Annual Meeting. The researchers noted this surgical de-escalation allows significant reduction of serious post-operative morbidity After the session, Oncology Times correspondent Peter Goodwin learned about more study details from Jean-Marc Classe, MD, PhD, Professor of Surgery in the Department of Surgical Oncology in the Institut de Cancérologie de l'Ouest and Nantes University in Western France.

Oncology Times - OT Broadcasts from the iPad Archives
Asciminib May Be a Safer, More Effective Treatment for Patients With Newly Diagnosed Chronic Myeloid Leukemia

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Jun 19, 2024 9:25


Primary results from ASC4FIRST trial, the first study in chronic myeloid leukemia comparing current standard-of-care frontline tyrosine kinase inhibitors with the novel agent asciminib in newly diagnosed patients, were reported at the 2024 ASCO Annual Meeting. First author Timothy Hughes MD, Consultant Hematologist with the Royal Adelaide Hospital, the South Australian Health and Medical Research Institute, and the University of Adelaide in Australia, reported higher efficacy in terms of major molecular responses and lower toxicity with asciminib. After his talk in Chicago, he met up with Oncology Times reporter, Peter Goodwin.

Oncology Times - OT Broadcasts from the iPad Archives
Trastuzumab Deruxtecan Delays Progression in HR+, HER2-low, and HER2 Ultralow Breast Cancer After Endocrine Therapy

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Jun 18, 2024 8:13


Data from the DESTINY Breast06 trial using the antibody-drug conjugate trastuzumab deruxtecan to treat patients with estrogen receptor positive (HR+), human epidermal growth factor receptor-low (HER2-low), and HER2-ultralow breast cancer after endocrine therapy, show longer progression-free survival in comparison with standard chemotherapy. After announcing the results at the 2024 ASCO Annual Meeting, first author Giuseppe Curigliano, MD, PhD, Director of Early Drug Development for the Innovative Therapies Division of the European Institute of Oncology, discussed the findings with Oncology Times correspondent Peter Goodwin

Oncology Times - OT Broadcasts from the iPad Archives
Chemotherapy Before and After Surgery Improved Outcomes for Patients With Resectable Locally Advanced Esophageal Adenocarcinoma

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Jun 18, 2024 6:52


Treatment with perioperative chemotherapy, with chemotherapy before and after surgery, brought superior outcomes for patients with locally advanced esophageal adenocarcinoma, in research reported to the 2024 ASCO Annual Meeting. Lead author Jens Höppner FAChirg, FACS, MD, Director of the Department of Surgery in the University Medical Center at the University of Bielefeld in Germany, spoke with Oncology Times reporter Peter Goodwin about his group’s comparison of neoadjuvant therapy using the CROSS (41.4 Gy plus carboplatin/paclitaxel) regimen followed by surgery, with the use of an alternative protocol: perioperative FLOT (5-FU/ leucovorin/oxaliplatin/docetaxel) and surgery, in which chemotherapy is given both before and after curative surgery.

The Country
The Country 13/06/24: Peter Goodwin talks to Jamie Mackay

The Country

Play Episode Listen Later Jun 13, 2024 2:00


Brandt's field operation manager says a huge team effort to put together the site at this year's Fieldays has paid off - Brandt won the best outdoor site over 400m2.See omnystudio.com/listener for privacy information.

The Country
The Country Full Show: Thursday, June 13, 2024

The Country

Play Episode Listen Later Jun 13, 2024 37:51


Jamie Mackay talks to David Seymour, Nicola Willis, Sir David Fagan, Bruce Weir, Peter Goodwin, Kieran McAnulty, Nadine Tunley, Mark de Lautour, and Gerard Vaughan.See omnystudio.com/listener for privacy information.

Oncology Times - OT Broadcasts from the iPad Archives
Study Supports Osimertinib as Standard of Care for Patients With Locally Advanced EGFR-Mutated NSCLC

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Jun 11, 2024 8:50


New data from the Phase III LAURA study, reported in Chicago at the ASCO 2024 Annual Meeting Plenary Session, suggest that the tyrosine kinase inhibitor osimertinib could become standard of care for treating patients whose unresectable locally advanced lung cancers test positive for mutated epidermal growth factor receptor (EGFR) and have no progression after definitive chemoradiotherapy. In Chicago, Oncology Times reporter Peter Goodwin met up with lead author of the LAURA study, Suresh S. Ramalingam MD, Executive Director of the Winship Cancer Institute at Emory University School of Medicine in Atlanta.

Oncology Times - OT Broadcasts from the iPad Archives
Study Finds Durvalumab Improved Progression-Free and Overall Survival in Limited Stage Small Cell Lung Cancer

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Jun 11, 2024 11:34


When the immune checkpoint inhibitor durvalumab was added to standard-of-care chemoradiation treatment for patients with limited-stage small-cell lung cancer, it brought a “statistically significant and clinically meaningful” improvement in overall and progression-free survival, compared to adding placebo. This was in data from the ADRIATIC study reported in the Plenary Session at the 2024 ASCO Annual Meeting in Chicago. Peter Goodwin was there for Oncology Times, where he talked with the lead author of the new research, David Spigel, MD, Chief Scientific Officer at Sarah Cannon Research Institute in Nashville, TN.

Oncology Times - OT Broadcasts from the iPad Archives
German Study Finds New Regimen for Hodgkin Lymphoma More Effective, Less Toxic

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Jun 11, 2024 17:36


An improvement over standard care in both efficacy and safety of a new combination regimen for treating Hodgkin lymphoma was discussed at the 2024 ASCO Annual Meeting in Chicago. The six-drug BrECADD regimen was compared with the high-achieving German-originated BEACOPP chemotherapy that has been widely adopted as standard of care. During the conference, Oncology Times reporter Peter Goodwin met up with Peter Borchmann, MD, PhD, the lead author of the new research and Chair of the German Hodgkin Study Group at the University Hospital of Cologne in Germany.

Oncology Times - OT Broadcasts from the iPad Archives
Earliest Detection of Cancer by Artificial Intelligence Analysis of Circulating Cell-Free DNA Fragmentomes

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later May 29, 2024 13:46


A new blood test that uses artificial intelligence to analyze circulating molecular markers for the earliest signs of ovarian and other cancers has been reported by researchers. At the AACR 2024 Annual Meeting in San Diego, Victor Velculescu, MD, PhD, Co-Director of the Cancer Genetics & Epigenetics Program at Johns Hopkins Kimmel Cancer Center, reported his group's validation of the test that assesses the pattern of circulating fragments of tumor DNA, known as fragmentomes. After discussing the findings at an AACR press briefing, Velculescu joined Peter Goodwin in the OncTimesTalk podcast studio to discuss the clinical implications.

Oncology Times - OT Broadcasts from the iPad Archives
Kinase Inhibitor Delivers Synthetic Lethality to Enhance Radiotherapy in Glioblastoma

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later May 29, 2024 10:31


The 2024 AACR Annual Meeting heard that an “efficacy signal” was detected in an international Phase I study of a new radiosensitizer, tested as adjunctive therapy (combined with standard radiation plus temozolomide) in patients with recurrent glioblastoma. After reporting his group's early findings of AZD1390, an inhibitor of ataxia telangiectasia mutated (ATM) kinase studied in 115 patients with recurrent or newly diagnosed glioblastoma, first author Jonathan T. Yang MD, PhD, previously from the Memorial Sloan Kettering Cancer Center and now at UW Medicine, stepped into the Oncology Times studio at the AACR conference to tell OncTimesTalk's reporter Peter Goodwin about the safety of this new agent and the clinical value it could bring in glioblastoma.

Oncology Times - OT Broadcasts from the iPad Archives
mRNA Vaccine + Checkpoint Inhibitor Combo Had Low Toxicity With Evidence of Efficacy in Advanced NSCLC

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later May 29, 2024 8:21


A combination of a new mRNA vaccine used together with a programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor to treat patients with lung cancer was markedly less toxic than a combination of the same vaccine with chemotherapy. However, it was apparently just effective. This is according to findings from a study reported to the 2024 AACR Annual Meeting. The randomized study, led by the researchers at the Moffitt Cancer Center, looked at a combination of the mRNA-based active cancer vaccine BI1361849 combined with the anti-PD-L1 checkpoint inhibitor durvalumab with or without the anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) checkpoint inhibitor tremelimumab immunotherapy. After announcing the findings at the AACR, presenting author Dung-Tsa Chen, PhD, Senior Member in the Department of Biostatistics & Informatics, Special Clinical Trial Design, and Data Analysis at the Moffitt Cancer Center, called in to discuss the new data with OncTimesTalk correspondent Peter Goodwin.

Oncology Times - OT Broadcasts from the iPad Archives
Exercise Deters Prostate Cancer Death & Progression

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later May 16, 2024 10:24


Findings from a new study support a body of evidence showing that physical exercise can bring benefits to patients with advanced prostate cancer. Data from an intervention study reported at the AACR Annual Meeting 2024 are consistent with mounting epidemiological evidence showing that regular physical exercise can help patients with advanced or metastatic prostate cancer “deter” death, slow disease progression, and improve quality of life. Stacey A. Kenfield, ScD, Professor of Urology and the Helen Diller Family Chair in Population Science for Urologic Cancer at the University of California San Francisco (UCSF), reported early data from the INTERVAL-GAP4 trial. Together with her colleague, June Chan, ScD, Professor of Epidemiology & Biostatistics in Urology at UCSF, she called into the Oncology Times studio at the San Diego conference to tell OncTimesTalk anchor, Peter Goodwin, about the newest findings and recommendations for using physical exercise as a form of therapy for patients with prostate and other cancers.

Oncology Times - OT Broadcasts from the iPad Archives
Clinical Study Shows Selective PARP 1 Inhibitor More Effective, Less Toxic

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later May 16, 2024 17:35


An early study using selective inhibition of the Poly (ADP-ribose) polymerase (PARP) has provided evidence it could bring greater cancer control with less toxicity than the well-proven non-selective PARP 1 and PARP 2 inhibitors already in use for treating a number of tumor types. At the AACR Annual Meeting 2024, Timothy Yap, PhD, MD, MBBS, Vice President and Head of Clinical Development in the Therapeutics Discovery Division at the University of Texas MD Anderson Cancer Center, reported early data from the PETRA study looking at the selective PARP 1 inhibitor saruparib under investigation as a potentially safer, yet more effective, alternative to the non-selective PARP 1/PARP 2 inhibitors currently licensed for prostate, ovarian, breast, and other cancers. After announcing the new research findings at a clinical session at AACR, he met up with Oncology Times reporter Peter Goodwin to discuss the new data and their clinical potential.

Oncology Times - OT Broadcasts from the iPad Archives
Bispecific Dual Checkpoint Blockade Extends Life & Slows Progression in Gastric & GE Junction Cancers

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later May 16, 2024 9:31


Double checkpoint blockade using a single bispecific agent could become the new standard for treating advanced gastric cancer regardless of PD-L1 status, according to research reported at the AACR Annual Meeting 2024. The investigational bispecific antibody drug cadonilimab (used with chemotherapy) significantly extended life and delayed disease progression among patients with HER2-negative advanced or metastatic gastric or gastroesophageal junction cancers reported from Chinese investigators. The first author of the report, Jiafu Ji, MD, PhD, DrPH, FACS, FRCS, Fellow of the Chinese Academy of Medical Science, as well as Professor and Chief of the Gastrointestinal Cancer Center at Peking University Cancer Hospital and the Beijing Institute for Cancer Research in China, called into the Oncology Times office at AACR after his talk to discuss his team's findings with Peter Goodwin, an OncTimesTalk correspondent.

Oncology Times - OT Broadcasts from the iPad Archives
Polyepitopic Personalized Vaccine Brought Durable Immune Responses & Clinical Benefit in Resected Head & Neck Cancers

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later May 2, 2024 13:00


Designed with the help of artificial intelligence to recognize multiple genetic features of each patient's tumor, a small clinical trial of a personalized therapeutic vaccine has shown durable tumor-specific immune responses in patients with surgically resected HPV-negative head and neck squamous cell cancer. The vaccine also prevented relapse in some patients. At the AACR Annual Meeting 2024, Olivier Lantz, MD, PhD, Head of the Clinical Immunology Laboratory at the Institut Curie Hospital in Paris, reported data using a “neoantigen-based vaccine” specifically designed to recognize multiple genetic features unique to each patient's tumor. During the conference, Lantz called into the OncTimesTalk studio to tell Peter Goodwin about the clinical options that could develop from such highly personalized vaccines.

Oncology Times - OT Broadcasts from the iPad Archives
Exosome-Based Liquid Biopsy Promises Very Early Pancreatic Cancer Detection

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later May 2, 2024 12:50


An opportunity to detect pancreatic cancer at stages where early intervention can greatly extend life and even make cure possible seems to be on offer, according to findings from a study of a new liquid biopsy method based on so-called exosomes: subcellular molecules shed into the circulation by cancer cells. At the AACR Annual Meeting 2024 in San Diego, Peter Goodwin talked with Ajay Goel, PhD, AGAF, senior author of the study and Chair of the Molecular Diagnostics and Experimental Therapeutics in the Beckman Research Institute at City of Hope in Los Angeles.

Oncology Times - OT Broadcasts from the iPad Archives
Bispecific T-cell Engager Antibody Brings Deep, Durable Remissions in R/R Multiple Myeloma

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later May 2, 2024 15:07


Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, brought robust clinical benefit to patients with relapsed or refractory multiple myeloma, including those in difficult-to-treat subgroups, in a multi-center, international study reported to the 2024 American Association for Cancer Research Annual Meeting. After giving his talk in San Diego, lead author Sundar Jagannath MBBS, Professor of Medicine, Hematology and Medical Oncology and Director of the Center of Excellence for Multiple Myeloma at the Icahn School of Medicine at Mount Sinai in New York, met up with OncTimesTalk correspondent Peter Goodwin to discuss the therapeutic progress the drug offers.

Oncology Times - OT Broadcasts from the iPad Archives
Radiotherapy Boost Protects Young Patients With Early Breast Cancer, High Dose Boost Not Needed

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Apr 29, 2024 8:38


The value of adding a radiation boost to postoperative radiotherapy for patients younger than 50 with early breast cancer has been confirmed by 10 years of data from the Young Boost trial conducted in the Netherlands. However, by randomizing patients between the standard radiation boost and a lower dose boost, the study demonstrated comparable efficacy for the two boost regimens, with less toxicity among patients receiving the low boost. The trial findings were reported by Sophie Bosma, MD, PhD, Radiation Oncologist from The Netherlands Cancer Institute in Amsterdam at the 14th European Breast Cancer Conference held in Milan. After her talk, she discussed the findings with Peter Goodwin.

Oncology Times - OT Broadcasts from the iPad Archives
Mesh-Supported Prepectoral Method of Breast Reconstruction After Breast Cancer Surgery

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Apr 29, 2024 10:27


Higher rates of satisfaction and psychosocial well-being and low complication rates were reported by patients who had a new mesh-supported prepectoral method of breast reconstruction using titanized mesh pockets after their surgery for breast cancer. At the 14th European Breast Cancer Conference in Milan, Stefan Paepke, MD, from the Interdisciplinary Breast Centre at the Technical University of Munich in Germany, said the technique prevents the unnatural breast mobility patients can experience after reconstruction, sometimes called jumping breasts. After reporting his group's 24-month follow-up data from the prospective international mesh-supported, pre-pectoral breast reconstruction trial (PRO-Pocket Trial) at the conference, he discussed the findings with Peter Goodwin.

Oncology Times - OT Broadcasts from the iPad Archives
Breast-Conserving Therapy Effective for Ductal Carcinoma in Situ, But Questions Remain

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Apr 26, 2024 15:40


A 30-year-long population-based study, reported at the 14th European Breast Cancer conference held in Milan, Italy, showed that breast-conserving therapy for ductal carcinoma in situ (DCIS) had become increasingly effective in preventing the emergence of breast cancer over the long term, but that there were still unanswered questions. The population-based Netherlands Cancer Registry retrospective cohort study of 25,719 women with DCIS diagnosed from 1989 up to 2021 (all of whom were treated with standard conservative therapy) found there were successes and limitations with the current standard of care for DCIS. Surprisingly, long-term risk appeared to have been unrelated to tumor grade. Also, despite a continuing improvement in outcomes during this period, the investigators concluded that specific molecular predictors of outcome still needed to be identified to distinguish intrinsically low-risk tumors (that did not require even conservative therapy) from those that carry higher risk and are highly likely to benefit from breast-conserving surgery and radiotherapy. After reporting the study findings in Milan, study author Adri Voogd, PhD, Associate Professor of Clinical Epidemiology in the Faculty of Health, Medicine, and Life Sciences at Maastricht University, Maastricht, The Netherlands, discussed their clinical implications with Peter Goodwin.

Oncology Times - OT Broadcasts from the iPad Archives
Three-Node Breast Cancer Spread: Most Patients Can Safely Avoid Axillary Dissection

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Apr 26, 2024 9:42


Most patients whose breast cancer has spread to more than three lymph nodes can nevertheless be spared extensive axillary dissection, according to the findings of a study presented at the 2024 European Breast Cancer Conference in Amsterdam, The Netherlands. Annemiek van Hemert, a Medical Doctor and PhD candidate at the Surgical Oncology Department of the Antoni van Leeuwenhoek-Netherlands Cancer Institute in Amsterdam, The Netherlands, reported her findings from a study using the MARI protocol (marking axillary lymph nodes with radioactive iodine seeds) that predicts cancer outcomes. The protocol was developed at the AVL Hospital in 2014 and is now being used in several Dutch hospitals. After her session at the Milan conference, van Hemert talked with OncTimesTalk correspondent Peter Goodwin about the clinical implications of her group's findings.

Oncology Times - OT Broadcasts from the iPad Archives
Artificial Intelligence Tool Predicts Postoperative Radiotherapy Lymphedema

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Apr 15, 2024 34:36


Artificial intelligence is being harnessed by a team of researchers at Leicester University in the United Kingdom to predict the risk of lymphedema (and potentially other toxicities) from the use of postoperative radiation therapy for breast cancer. The 2024 European Breast Cancer Conference heard the latest news on an artificial intelligence tool that promises to help cancer clinicians individualize radiotherapy regimens after surgery to minimize toxicity. Tim Rattay, MBChB, PhD, Associate Professor in Breast Surgery in the Leicester Cancer Research Centre at the University of Leicester and Consultant Breast Surgeon at the University Hospitals of Leicester in the UK, told the conference about his group's machine-learning algorithm, PRE-ACT (Prediction of Radiotherapy side Effects using explainable AI for patient Communication and Treatment modification), that predicts post-operative lymphedema. After reporting his research in Milan, Rattay called into the OncTimesTalk studio to give Peter Goodwin the details.

Oncology Times - OT Broadcasts from the iPad Archives
Neoadjuvant Pembrolizumab Improves High-Risk Early Breast Cancer Outcomes

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Apr 15, 2024 8:47


New data from the Phase III KEYNOTE-756 clinical trial show that adding pembrolizumab immunotherapy to chemotherapy before and after surgery for high-risk breast cancer (which was estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative) resulted in better outcomes for patients regardless of their age or menopausal status. The findings were presented at the 14th European Breast Cancer Conference by KEYNOTE-756 study co-author Heather McArthur, MD, MPH, Clinical Director of the Breast Cancer Program and Komen Distinguished Chair in Clinical Breast Research at the UT Southwestern Medical Center. She reported the findings at the Milan conference on behalf of her co-author Javier Cortés MD, Head of the International Breast Cancer Centre in Barcelona, Spain. After her talk in Milan, McArthur called into the OncTimesTalk Studio to talk about the findings with Peter Goodwin.

Pediatric Physical Therapy - Pediatric Physical Therapy Podcast

The Pediatric Physical Therapy Podcast March, 2024 Edition: AN INTERVIEW WITH: Eilish M Byrne PT, DSc, PCS, CNT, Assistant Professor, Camino Hospital and Stanford Children's Hospital, California, Visiting Professor University of St Augustine, San Marcos, California. In conversation with Peter Goodwin, Editor, The Pediatric Physical Therapy Podcast (March, 2024 Edition) DESCRIPTION: Dr. Byrne discusses the research her ream has published in Pediatric Physical Therapy, Volume 36, Number 2, 2024 on: “Introducing the i-Rainbow- An evidence-based, parent-friendly care pathway designed for even the most critically ill infant in the Neonatal Intensive Care setting.” AUTHORS: Eilish M. Byrne, Katherine Hunt and Melissa Scala SUMMARY: This study investigated the feasibility and effectiveness of a novel, evidence-based developmental care pathway to be used by healthcare providers and parents in the neonatal intensive care setting. PURPOSE: This study investigated the feasibility and effectiveness of a novel, evidence-based developmental care pathway to be used by healthcare providers and parents in the neonatal intensive care setting (NICU). The iRainbow is based on current evidence and responds to individual infant health status. It is not base on infant age. METHODS: After development and implementation of the iRainbow, pre-and post- implementation nurse and parent survey data were collected, and pre- and post-developmental care rates were compared. RESULTS: After iRainbow implementation, disagreement among providers on appropriate developmental care interventions significantly decreased, total minutes of daily developmental care and swaddled holding increased significantly, and parents reported that they would recommend the tool. CONCLUSION: The iRainbow is a unique, parent-friendly, infant-based tool that guides sensory interventions in the NICU by staging infants based on cardiorespiratory status and physiologic maturity, not age. The iRainbow improved the delivery of developmental care activities in our unit and was well received by parents and nurses. KEYWORDS: iRainbow, Neonatal Intensive Care Unit, Neonatal Therapy, Developmental Care, Neonatal Sensory Interventions, Neonatal Care Path, Family Education WHAT THIS EVIDENCE ADDS: Current evidence: There are many studies and programs demonstrating the benefits of providing evidence-based developmental interventions for both neonates and caregivers.1-4 Gap in the evidence: There is less agreement regarding the safety and timing of developmental interventions7-9, and what does exist tends to rely on gestational age, while recommending performing activities per infant tolerance.5,6 However, this approach can be problematic because preterm infants progress at variable rates, and infant tolerance is not objectively defined. How does this study fill this gap? This study provides objective clinical criteria to define neonate tolerance for intervention guided by the cardiorespiratory stability of the infant, and in later stages, behavior cues of the infant, not gestational age. Implication of all the evidence: Optimal timing of and tolerance to evidence-based developmental interventions in the NICU is still being described. Relying solely on gestational ages may not be ideal for many infants. The iRainbow serves as a valuable tool to objectively identify an infant's readiness to participate in a developmental care program.